Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Epithelial Tissues: Overview01:22

Classification of Epithelial Tissues: Overview

Epithelial tissues are classified according to the shape of the cells and the number of cell layers formed. Cell shapes can be squamous (flattened and thin), cuboidal (square-like, as wide as it is tall), or columnar (rectangular, taller than it is wide). Additionally, the nucleus shape helps identify the type of epithelial cells. Squamous cells have flattened disc-shaped nuclei, cuboidal cells have spherical nuclei, and columnar cells have elongated nuclei.
Based on the number of cell layers,...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex analyticity of the nonlinear Poisson-Boltzmann equation for the interface problem with random domains.

Numerische mathematik·2026
Same author

Analytic regularity of strong solutions for the complexified stochastic nonlinear Poisson-Boltzmann Equation.

Computers & mathematics with applications (Oxford, England : 1987)·2026
Same author

The Relationship Between MOTS-c K14Q Polymorphism and Sarcopenia, Blood Lipids, and Mental Health in Older Korean Adults.

Biomedicines·2024
Same author

Uncertainty quantification of receptor ligand binding sites prediction.

ArXiv·2024
Same author

Inferring Drug Set and Identifying the Mechanism of Drugs for PC3.

International journal of molecular sciences·2024
Same author

An Agrigenomics Trifecta: Greenhouse Gas Drawdown, Food Security, and New Drugs.

Cold Spring Harbor perspectives in biology·2023

Related Experiment Video

Updated: May 20, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Pathway-based classification of cancer subtypes.

Shinuk Kim1, Mark Kon, Charles DeLisi

  • 1Bioinformatics program, Boston University, Boston, MA 02215, USA.

Biology Direct
|July 5, 2012
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for cancer marker analysis using stable, pathway-based gene expression profiles. This approach improves the reproducibility of cancer biomarkers for better clinical applications.

Related Experiment Videos

Last Updated: May 20, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

  • Genomics
  • Bioinformatics
  • Cancer Research

Background:

  • Gene expression profiles are used for cancer classification but often lack reproducibility across datasets.
  • Standard gene markers are unstable, limiting their clinical utility in cancer diagnosis and prognosis.
  • A novel, standardized method is needed to improve the reliability of molecular markers for cancer subtypes.

Purpose of the Study:

  • To introduce a standardized method for representing cancer markers using 2-level hierarchical feature vectors.
  • To enhance cancer subtype discrimination by incorporating pathway-level activation features alongside gene-level information.
  • To improve the reproducibility and clinical usefulness of genomic markers in cancer research.

Main Methods:

  • Developed a 2-level hierarchical feature vector system combining basic gene expression and pathway markers.
  • Utilized gene set enrichment algorithms (e.g., GSEA) to derive pathway-level activation features.
  • Applied the method to analyze breast cancer metastasis and ovarian cancer survival datasets.

Main Results:

  • Pathway-based markers demonstrated significantly higher reproducibility compared to standard gene markers across datasets.
  • Achieved improved discrimination for breast cancer metastasis and ovarian cancer survival time using the new method.
  • Identified specific pathways (Type_1 diabetes mellitus, Cytokine-cytokine receptor interaction, Hedgehog signaling) and key cancer genes with prognostic value.

Conclusions:

  • Standardized analysis of genomic data, particularly using pathway-based biomarkers, is crucial for clinical applications.
  • The proposed paradigm enhances biomarker-based cancer analysis, leading to clinically reproducible canonical biomarkers.
  • This approach is expected to improve the clinical utility of high-throughput genomic data for cancer diagnosis and prognosis.